Edward White
Edward P. White is the managing director, senior biotechnology analyst, at H.C. Wainwright & Co., where his research coverage focus is on small to mid-cap life sciences companies. He formerly was a senior biotech equity research analyst at FBR & Co. Prior to FBR, he worked in several healthcare equity research groups, including Deutsche Bank Securities and BMO Capital Markets. He also worked for six years as a Senior Buyside Healthcare Research Analyst at Mitsubishi UFJ Trust.
Recent Articles about Valneva SE
Biotech Co.'s Sales Could Grow To US$310 Million in 2028 01/10/2024
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report.
Antibodies from Vaccine Remain Two Years Out 12/06/2023
This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report.
New Vaccine for Chikungunya Shown To Be Safe in Youths 09/01/2023
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report.
© 2024 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
